drugset / Trial / NCT00658684

Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.

NCT00658684

Phase 3 Completed 153 enrolled Pfizer
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.

Timeline

Start
2008-02
Primary completion
2009-08
Completion
2009-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg
Subject Fesoterodine Other / unclassified 8 mg

Indications